The role of HIV-1 minority variants on transmission, pathogenesis, and virologic failure to antiretroviral regimens has been explored; however, most studies of low-level HIV-1 drug-resistant variants have focused in single target regions. Here we used a novel HIV-1 genotypic assay based on deep sequencing, DEEPGEN (Gibson et al 2014 Antimicrob Agents Chemother 58∶2167) to simultaneously analyze the presence of minority variants carrying mutations associated with reduced susceptibility to protease (PR), reverse transcriptase (RT), and integrase strand transfer integrase inhibitors (INSTIs), as well as HIV-1 coreceptor tropism. gag-p2/NCp7/p1/p6/pol-PR/RT/INT and env/C2V3 PCR products were obtained from twelve heavily treatment-experienced patients experiencing virologic failure while participating in a 48-week dose-ranging study of elvitegravir (GS-US-183-0105). Deep sequencing results were compared with (i) virological response to treatment, (ii) genotyping based on population sequencing, (iii) phenotyping data using PhenoSense and VIRALARTS, and (iv) HIV-1 coreceptor tropism based on the phenotypic test VERITROP. Most patients failed the antiretroviral regimen with numerous pre-existing mutations in the PR and RT, and additionally newly acquired INSTI-resistance mutations as determined by population sequencing (mean 9.4, 5.3, and 1.4 PI- RTI-, and INSTI-resistance mutations, respectively). Interestingly, since DEEPGEN allows the accurate detection of amino acid substitutions at frequencies as low as 1% of the population, a series of additional drug resistance mutations were detected by deep sequencing (mean 2.5, 1.5, and 0.9, respectively). The presence of these low-abundance HIV-1 variants was associated with drug susceptibility, replicative fitness, and coreceptor tropism determined using sensitive phenotypic assays, enhancing the overall burden of resistance to all four antiretroviral drug classes. Further longitudinal studies based on deep sequencing tests will help to clarify (i) the potential impact of minority HIV-1 drug resistant variants in response to antiretroviral therapy and (ii) the importance of the detection of HIV minority variants in the clinical practice.

Gilead Sciences Inc Foster City California United States of America

Institute of Organic Chemistry and Biochemistry Prague Czech Republic

University Hospital Translational Laboratory University Hospitals Case Medical Center Cleveland Ohio United States of America

University Hospital Translational Laboratory University Hospitals Case Medical Center Cleveland Ohio United States of America; Department of Pathology Case Western Reserve University Cleveland Ohio United States of America

Zobrazit více v PubMed

Paredes R, Clotet B (2010) Clinical management of HIV-1 resistance. Antiviral Res 85: 245–265. PubMed

Zolopa AR (2010) The evolution of HIV treatment guidelines: current state-of-the-art of ART. Antiviral Res 85: 241–244. PubMed

Fast PE, Price MA, Rida WN, Kamali A, Karita E (2013) WHO's new guidelines for antiretroviral treatment. Lancet 382: 1778–1779. PubMed

Richardson ET, Grant PM, Zolopa AR (2013) Evolution of HIV treatment guidelines in high and low-income countries: Converging recommendations. Antiviral research. PubMed PMC

Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, et al. (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. Journal of medicinal chemistry 51: 5843–5855. PubMed

Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, et al. (2006) Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. JMedChem 49: 1506–1508. PubMed

Zolopa A, Gallant J, Cohen C, Sax P, Dejesus E, et al. (2012) Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients. Journal of the International AIDS Society 15: 18219.

Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, et al. (2011) In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrobial Agents and Chemotherapy 55: 813–821. PubMed PMC

Castagna A, Maggiolo F, Penco G, Wright D, Mills A, et al. (2014) Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. The Journal of infectious diseases. PubMed PMC

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, et al. (2013) Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. PubMed

Lewin SR, Rouzioux C (2011) HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 25: 885–897. PubMed

Archin NM, Margolis DM (2014) Emerging strategies to deplete the HIV reservoir. Current opinion in infectious diseases 27: 29–35. PubMed PMC

Deeks SG (2003) Treatment of antiretroviral-drug-resistant HIV-1 infection. The Lancet 362: 2002–2011. PubMed

Tang JW, Pillay D (2004) Transmission of HIV-1 drug resistance. JClinVirol 30: 1–10. PubMed

Menendez-Arias L (2013) Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral research 98: 93–120. PubMed

Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. JVirol 69: 5087–5094. PubMed PMC

Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117–122. PubMed

Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, et al. (1996) Basic concepts in RNA virus evolution. FASEB J 10: 859–864. PubMed

Eigen M (1993) Viral quasispecies. SciAm 269: 42–49. PubMed

Domingo E, Menendez-Arias L, Quinones-Mateu ME, Holguin A, Gutierrez-Rivas M, et al. (1997) Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. ProgDrug Res 48: 99–128. PubMed

Quinones-Mateu ME, Arts EJ (2001) HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution. In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F et al.., editors. HIV Sequence Compendium 2001. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory. pp. 134–170.

Quinones-Mateu ME, Arts EJ (2006) Virus fitness: concept, quantification, and application to HIV population dynamics. Current Topics in Microbiology and Immunology 299: 83–140. PubMed

Preston BD, Dougherty JP (1996) Mechanisms of retroviral mutation. Trends in Microbiology 4: 16–21. PubMed

Quinones-Mateu ME, Arts EJ (2002) Fitness of drug resistant HIV-1: methodology and clinical implications. Drug ResistUpdat 5: 224–233. PubMed

Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, et al. (1993) Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365: 671–673. PubMed

Church JD, Jones D, Flys T, Hoover D, Marlowe N, et al. (2006) Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. The Journal of molecular diagnostics: JMD 8: 430–432; quiz 527. PubMed PMC

Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, et al. (2006) Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. Journal of clinical microbiology 44: 2612–2614. PubMed PMC

Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, et al. (1993) Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques 15: 120–127. PubMed

Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, et al. (2003) Accuracy of the TRUGENE HIV-1 genotyping kit. Journal of clinical microbiology 41: 1586–1593. PubMed PMC

Li JZ, Kuritzkes DR (2013) Clinical implications of HIV-1 minority variants. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 56: 1667–1674. PubMed PMC

Gianella S, Richman DD (2010) Minority variants of drug-resistant HIV. The Journal of infectious diseases 202: 657–666. PubMed PMC

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA: the journal of the American Medical Association 305: 1327–1335. PubMed PMC

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, et al. (2011) Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 53: 732–742. PubMed

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, et al. (2011) Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. The Journal of infectious diseases 203: 237–245. PubMed PMC

Goodman DD, Zhou Y, Margot NA, McColl DJ, Zhong L, et al. (2011) Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 25: 325–333. PubMed

Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, et al. (2010) Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. The Journal of infectious diseases 201: 662–671. PubMed PMC

Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, et al. (2006) Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20: 701–710. PubMed

Lalonde MS, Troyer RM, Syed AR, Bulime S, Demers K, et al. (2007) Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. JClinMicrobiol 45: 2604–2615. PubMed PMC

Stekler JD, Ellis GM, Carlsson J, Eilers B, Holte S, et al. (2011) Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PloS one 6: e28952. PubMed PMC

Avidor B, Girshengorn S, Matus N, Talio H, Achsanov S, et al. (2013) Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory. Journal of clinical microbiology 51: 880–886. PubMed PMC

Chang MW, Oliveira G, Yuan J, Okulicz JF, Levy S, et al. (2013) Rapid deep sequencing of patient-derived HIV with ion semiconductor technology. Journal of Virological Methods 189: 232–234. PubMed PMC

Dudley DM, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, et al. (2012) Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PloS one 7: e36494. PubMed PMC

Gibson RM, Meyer AM, Winner D, Archer J, Feyertag F, et al. (2014) Sensitive Deep Sequencing-based HIV-1 Genotyping Assay to Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as well as HIV-1 Coreceptor Tropism. Antimicrobial Agents and Chemotherapy 58: 2167–2185. PubMed PMC

Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, et al. (2013) Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. The Journal of infectious diseases 207: 893–897. PubMed PMC

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, et al. (2012) Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 26: 185–192. PubMed PMC

Codoner FM, Pou C, Thielen A, Garcia F, Delgado R, et al. (2011) Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PloS one 6: e19461. PubMed PMC

Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, et al. (2010) Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. JInfectDis 201: 814–822. PubMed

McColl DJ, Fransen S, Gupta S, Parkin N, Margot N, et al. (2007) Resistance and cross resistance to fist generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Antiviral Therapy 12: S11.

Weber J, Vazquez AC, Winner D, Rose JD, Wylie D, et al. (2011) Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3′Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy. Antimicrobial Agents and Chemotherapy 55: 3729–3742. PubMed PMC

Quinones-Mateu ME, Domingo E (1999) Nucleotide diversity in three different genomic regions of Venezuelan HIV type 1 isolates: a subtyping update. AIDS ResHumRetroviruses 15: 73–79. PubMed

Weber J, Quinones-Mateu ME (2007) Novel anti-HIV-1 screening system based on intact recombinant viruses expressing synthetic firefly and renilla luminescent proteins. AntivirTher 12: S155.

Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. AmJHyg 27 493–497.

Holland AU, Munk C, Lucero GR, Nguyen LD, Landau NR (2004) Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion. Virology 319: 343–352. PubMed

Weber J, Vazquez AC, Winner D, Gibson RM, Rhea AM, et al. (2013) Sensitive Cell-based Assay to Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism. Journal of clinical microbiology 51: 1517–1527. PubMed PMC

Weber J, Rose JD, Vazquez AC, Winner D, Margot N, et al. (2013) Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors. PloS one 8: e65631. PubMed PMC

Quinones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, et al. (2000) A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. JVirol 74: 9222–9233. PubMed PMC

Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2013) Update of the drug resistance mutations in HIV-1: March 2013. Topics in antiviral medicine 21: 6–14. PubMed PMC

Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947–2948. PubMed

Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Molecular biology and evolution 28: 2731–2739. PubMed PMC

Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, et al. (2007) Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. AntivirTher 12: 1097–1106. PubMed

Harrigan PR (2009) MOTIVATE tropism study group. Optimization of clinical cutoffs for determining HIV co-receptor use by population and “deep” sequencing methods. Infectious Diseases Society of America Philadelphia, PA.

Bunnik EM, Swenson LC, Edo-Matas D, Huang W, Dong W, et al. (2011) Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS pathogens 7: e1002106. PubMed PMC

Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ (2007) Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. Journal of Virology 81: 8258–8269. PubMed PMC

Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW (2007) Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome research 17: 1195–1201. PubMed PMC

Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, et al. (2009) Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. The Journal of infectious diseases 199: 693–701. PubMed

Messiaen P, Verhofstede C, Vandenbroucke I, Dinakis S, Van Eygen V, et al. (2012) Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. Virology 426: 7–11. PubMed

Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, et al. (2012) Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing. PloS one 7: e30118. PubMed PMC

D'Aquila RT, Geretti AM, Horton JH, Rouse E, Kheshti A, et al. (2011) Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing. AIDS Research and Human Retroviruses 27: 201–209. PubMed

Recordon-Pinson P, Papuchon J, Reigadas S, Deshpande A, Fleury H (2012) K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data. PloS one 7: e36549. PubMed PMC

Vandenhende MA, Bellecave P, Recordon-Pinson P, Reigadas S, Bidet Y, et al. (2014) Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure. PloS one 9: e86771. PubMed PMC

McColl DJ, Chen X (2010) Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral research 85: 101–118. PubMed

Dunne AL, Mitchell FM, Coberly SK, Hellmann NS, Hoy J, et al. (2001) Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 15: 1471–1475. PubMed

Ji H, Masse N, Tyler S, Liang B, Li Y, et al. (2010) HIV drug resistance surveillance using pooled pyrosequencing. PloS one 5: e9263. PubMed PMC

Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, et al. (2008) Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. Journal of Virology 82: 10747–10755. PubMed PMC

Bellecave P, Recordon-Pinson P, Papuchon J, Vandenhende MA, Reigadas S, et al. (2013) Detection of Low-Frequency HIV Type 1 Reverse Transcriptase Drug Resistance Mutations by Ultradeep Sequencing in Naive HIV Type 1-Infected individuals. AIDS Research and Human Retroviruses. PubMed

Gonzalez S, Tully DC, Gondwe C, Wood C (2013) Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing. Current HIV research 11: 43–49. PubMed PMC

Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, et al. (2009) Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PloS one 4: e6079. PubMed PMC

De Wolf H, Van Marck H, Mostmans W, Thys K, Vandenbroucke I, et al. (2011) HIV-1 nucleotide mixture detection in the virco((R))TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing. Journal of Virological Methods 175: 129–132. PubMed

Lee GQ, Swenson LC, Poon AF, Martin JN, Hatano H, et al. (2012) Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 “deep” sequencing. PloS one 7: e46181. PubMed PMC

Fisher R, van Zyl GU, Travers SA, Kosakovsky Pond SL, Engelbrech S, et al. (2012) Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. Journal of Virology 86: 6231–6237. PubMed PMC

Dudley DM, Gao Y, Nelson KN, Henry KR, Nankya I, et al. (2009) A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques 46: 458–467. PubMed

Weber J, Rangel HR, Chakraborty B, Tadele M, Martinez MA, et al. (2003) A Novel TaqMan Real-Time PCR Assay to Estimate ex vivo Human Immunodeficiency Virus type 1 Fitness in the Era of Multi-Target (pol and env) Antiretroviral Therapy. Journal of General Virology 84: 2217–2228. PubMed

Weber J, Weberova J, Carobene M, Mirza M, Martinez-Picado J, et al. (2006) Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods 136: 102–117. PubMed

Ibanez A, Clotet B, Martinez MA (2000) Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. The Journal of general virology 81: 85–95. PubMed

Kitrinos KM, Nelson JA, Resch W, Swanstrom R (2005) Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations. Journal of Virology 79: 10627–10637. PubMed PMC

Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW (2011) HIV-1 integrase inhibitor resistance and its clinical implications. The Journal of infectious diseases 203: 1204–1214. PubMed PMC

Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals